Page 11 - Cyte Contacts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |MaxCyte, Inc Announcements | MaxCyte, Inc : Participation in Upcoming Investor Conferences

Investegate announcements from MaxCyte, Inc., Participation in Upcoming Investor Conferences

United kingdomDavid deuchlerMary jane elliott chris welshPanmure gordonEmma earl freddy crossleyRupert deardenMaxcyte incGilmartin groupConsilium strategic communicationsA spectrum science companyUpcoming investorStifel healthcareStephens annual investmentFlow electroporationCyte contactsSpectrum science

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Communicationsmary jane elliott chris welshAdvisergilmartin groupdavid deuchlerMaxcyte incCall detailsinvestorsFlow electroporationCyte contactsGilmartin groupdavid deuchlerJoint corporate brokerpanmure gordonemma earlFreddy crossleycorporate brokingrupert

Investegate |MaxCyte, Inc Announcements | MaxCyte, Inc : Total Voting Rights and Block Listing Return

Investegate announcements from MaxCyte, Inc., Total Voting Rights and Block Listing Return

United kingdomDavid deuchlerChris welshMary jane elliottRon holtzPanmure gordonEmma earl freddy crossleyRupert deardenMaxcyte incGilmartin groupCompany common stockConsilium strategic communicationsCommon stockSchedule sixChief financialCyte contacts

Investegate |MaxCyte, Inc Announcements | MaxCyte, Inc : Signing of Strategic Platform License

Investegate announcements from MaxCyte, Inc., Signing of Strategic Platform License

United statesUnited kingdomCity ofDavid deuchlerChris welshMary jane elliottEmma earl freddy crossleyPanmure gordonRupert deardenMaxcyte incVertex pharmaceuticalsGilmartin groupHuman rights campaignVertex pharmaceuticals incorporatedConsilium strategic communicationsCyte signs strategic platform license

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™. | September 28, 2022

United statesUnited kingdomCity ofDavid deuchlerChris welshMary jane elliottEmma earl freddy crossleyPanmure gordonRupert deardenMaxcyte incVertex pharmaceuticalsGilmartin groupHuman rights campaignVertex pharmaceuticals incorporatedConsilium strategic communicationsFlow electroporation